Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

被引：0
|
作者：
Hasan, Md Kamrul [1 ]
Widhopf, George F., II [2 ]
Kipps, Thomas J. [1 ]
机构：
[1] Univ Calif San Diego, Moores Canc Ctr, Ctr Novel Therapeut, La Jolla, CA USA
[2] Ctr Novel Therapeut, Sch Med, La Jolla, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-191114
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Dong-Won Kang
    Li Wang
    Nicholas J. Short
    Alessandra Ferrajoli
    Yucai Wang
    Shouhao Zhou
    Chan Shen
    PharmacoEconomics, 2024, 42 : 409 - 418
  • [22] Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
    Tam, Constantine
    Munoz, Javier
    Cull, Gavin
    Opat, Stephen
    Allewelt, Heather
    Zhang, Xiaoping
    Stern, Jennifer C.
    Hilger, James
    By, Kunthel
    Cohen, Aileen
    Tedeschi, Alessandra
    HEMASPHERE, 2023, 7 (04):
  • [23] BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma
    Wiestner, Adrian
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 125 - 134
  • [24] Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma
    Nierengarten, Mary Beth
    CANCER, 2023, 129 (10) : 1466 - 1466
  • [25] Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells
    Desch, P.
    Asslaber, D.
    Kern, D.
    Schnidar, H.
    Mangelberger, D.
    Alinger, B.
    Stoecher, M.
    Hofbauer, S. W.
    Neureiter, D.
    Tinhofer, I.
    Aberger, F.
    Hartmann, T. N.
    Greil, R.
    ONCOGENE, 2010, 29 (35) : 4885 - 4895
  • [26] Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells
    P Desch
    D Asslaber
    D Kern
    H Schnidar
    D Mangelberger
    B Alinger
    M Stoecher
    S W Hofbauer
    D Neureiter
    I Tinhofer
    F Aberger
    T N Hartmann
    R Greil
    Oncogene, 2010, 29 : 4885 - 4895
  • [27] BUDGET IMPACT OF ZANUBRUTINIB FOR TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Xiao, Y.
    Gani, R.
    Xue, M.
    Tang, B.
    VALUE IN HEALTH, 2022, 25 (12) : S65 - S66
  • [28] Zanubrutinib, a promising treatment option for treatment-naive patients with chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (05): : 207 - 207
  • [29] Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma
    Tam, Constantine S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 32 - 34
  • [30] Bendamustine therapy in chronic lymphocytic leukemia
    Masiello, David
    Tulpule, Anil
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (10) : 1687 - 1698
12345